ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 996,64
0,49%
Dow Jones
38 852,27
0,46%
DAX
18 175,21
1,01%
Brent Oil
83,475
0,42%
Bitcoin
63 496,65
-0,79%
Registration Strip Icon for default Inscrivez-vous gratuitement pour obtenir des cotations en temps réel, des graphiques interactifs, un flux d'options en direct et plus encore.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Nuvalent Inc (NUVL)

  7. Nuvalent Inc (NUVL) Actualités

NUVL Nuvalent Inc

69,25
-1,10 (-1,56%)
Après les heures de négociation
Dernière mise à jour : 23:30:00
Retardé de 15 minutes
Nom Action Symbole Action Marché Type
Nuvalent Inc NUVL NASDAQ Action ordinaire
  Variation Action Variation Action% Cours Dernier Dernier échange
Upgrade Icon
-1,10 -1,56% 69,25 23:30:00
Ouverture Plus Bas Plus Haut Prix de clôture Clôture Veille
69,99 68,79 70,69 69,25 70,35
plus d'informations sur les cotations »

Actualités Recentes

Date Heure Source Titre
08/4/202422:30PRNUSNuvalent Presents New Preclinical Data Supporting Profiles..
05/3/202422:52PRNUSNuvalent to Present New Preclinical Data on HER2-Selective..
27/2/202413:00EDGAR2Form S-8 - Securities to be offered to employees in employee..
27/2/202412:42EDGAR2Form 10-K - Annual report [Section 13 and 15(d), not S-K..
27/2/202412:38EDGAR2Form 8-K - Current report
27/2/202412:30PRNUSNuvalent Highlights Pipeline Progress, Reiterates Key..
27/2/202412:15PRNUSNuvalent Receives U.S. FDA Breakthrough Therapy Designation..
12/2/202412:30PRNUSNuvalent Initiates the Phase 2 Portion of ALKOVE-1 Clinical..
01/2/202412:30PRNUSNuvalent to Participate in the Guggenheim Healthcare Talks..
09/1/202422:55EDGAR2Form 4 - Statement of changes in beneficial ownership of..
09/1/202422:54EDGAR2Form 4 - Statement of changes in beneficial ownership of..
09/1/202422:51EDGAR2Form 4 - Statement of changes in beneficial ownership of..
09/1/202422:49EDGAR2Form 4 - Statement of changes in beneficial ownership of..
09/1/202422:46EDGAR2Form 4 - Statement of changes in beneficial ownership of..
09/1/202422:40EDGAR2Form 8-K - Current report
08/1/202412:30PRNUSNuvalent Announces "OnTarget 2026" Operating Plan and Key..
28/12/202323:09EDGAR2Form 4 - Statement of changes in beneficial ownership of..
26/12/202322:31EDGAR2Form 144 - Report of proposed sale of securities
21/12/202312:30PRNUSNuvalent to Present at the 42nd Annual J.P. Morgan..
20/12/202322:56EDGAR2Form 4 - Statement of changes in beneficial ownership of..
20/12/202322:54EDGAR2Form 4 - Statement of changes in beneficial ownership of..
20/12/202322:51EDGAR2Form 4 - Statement of changes in beneficial ownership of..
20/12/202300:00EDGAR2Form 144 - Report of proposed sale of securities
18/12/202323:45EDGAR2Form 144 - Report of proposed sale of securities
18/12/202323:32EDGAR2Form 144 - Report of proposed sale of securities
18/12/202323:23EDGAR2Form 144 - Report of proposed sale of securities
30/11/202322:47EDGAR2Form 4 - Statement of changes in beneficial ownership of..
14/11/202312:50EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
14/11/202312:45EDGAR2Form 8-K - Current report
14/11/202312:30PRNUSNuvalent Highlights Corporate and Pipeline Achievements and..
03/11/202321:43EDGAR2Form 4 - Statement of changes in beneficial ownership of..
01/11/202311:30PRNUSNuvalent to Participate in the BMO Virtual BioPharma..
26/10/202322:47EDGAR2Form 4 - Statement of changes in beneficial ownership of..
25/10/202300:01EDGAR2Form 144 - Report of proposed sale of securities
17/10/202322:07EDGAR2Form 8-K - Current report
17/10/202322:05EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
17/10/202303:55PRNUSNuvalent Announces Pricing of Public Offering of Common..
16/10/202313:39EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
16/10/202313:30PRNUSNuvalent Announces Public Offering of Common Stock
13/10/202312:40EDGAR2Form 8-K - Current report
13/10/202312:30PRNUSNuvalent Reports Preliminary Phase 1 Clinical Data from..
06/10/202322:58EDGAR2Form 4 - Statement of changes in beneficial ownership of..
06/10/202322:56EDGAR2Form 4 - Statement of changes in beneficial ownership of..
04/10/202322:24EDGAR2Form 4 - Statement of changes in beneficial ownership of..
04/10/202322:12EDGAR2Form 144 - Report of proposed sale of securities
04/10/202322:05EDGAR2Form 8-K - Current report
04/10/202318:21PRNUSPreliminary Phase 1 Dose-Escalation Data from ALKOVE-1 Trial..
19/9/202322:45EDGAR2Form 4 - Statement of changes in beneficial ownership of..
18/9/202312:30PRNUSNuvalent to Present Preliminary Data from ALKOVE-1 Phase 1/2..
06/9/202322:36EDGAR2Form 4 - Statement of changes in beneficial ownership of..

Dernières Valeurs Consultées

NASDAQ
NUVL
Nuvalent
Delayed Upgrade Clock
ADVFN Logo

France
Société
Entreprise
Popular
Obtenir l'application

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés